Literature DB >> 10365804

HLA antigens in patients with interferon-alpha-induced autoimmune thyroid disorders in chronic hepatitis C.

S Kakizaki1, H Takagi, M Murakami, H Takayama, M Mori.   

Abstract

BACKGROUND/AIMS: To determine the immunological predisposition to autoimmune thyroid disorders induced by interferon-alpha therapy, human leukocyte antigen (HLA) was analyzed in patients with chronic hepatitis C who developed autoimmune thyroid disorders during or after treatment with interferon-alpha.
METHODS: Four hundred and thirty-nine patients with chronic hepatitis C (278 males and 161 females, aged 20-73 years) were treated with interferon-alpha (natural-alpha, 169; alpha-2a, 82; alpha-2b, 188) for 24 weeks.
RESULTS: Seventeen of 439 (3.9%) patients developed symptomatic autoimmune thyroid disorders; these included nine cases of hyperthyroidism and eight cases of hypothyroidism. The incidence of HLA-A2, B46 and Cw7 increased in patients with interferon-alpha-induced autoimmune thyroid disorders. Especially, the incidence of HLA-A2 (15/17; 88.2%) was significantly higher than that observed in the general population in Japan (corrected p-value (p(c)): p(c)<0.003). The odds ratios for the relative risk of the autoimmune thyroid disorders were A2, 10.6 [95% confidence interval, 2.4-46.5]; B46, 4.8 [1.6-14.0]; and Cw7, 3.0 [1.1-7.9].
CONCLUSIONS: Our study revealed that HLA-A2 is highly linked to the autoimmune thyroid disorders induced by interferon-alpha-therapy in patients with chronic hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10365804     DOI: 10.1016/s0168-8278(99)80131-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  16 in total

Review 1.  Thyroid dysfunction from antineoplastic agents.

Authors:  Ole-Petter Riksfjord Hamnvik; P Reed Larsen; Ellen Marqusee
Journal:  J Natl Cancer Inst       Date:  2011-10-18       Impact factor: 13.506

2.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

Review 3.  Hepatitis C and interferon induced thyroiditis.

Authors:  Yaron Tomer
Journal:  J Autoimmun       Date:  2010-05       Impact factor: 7.094

Review 4.  Opportunistic autoimmune disorders: from immunotherapy to immune dysregulation.

Authors:  Yi-chi M Kong; Wei-Zen Wei; Yaron Tomer
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

Review 5.  Environmental triggers of thyroiditis: hepatitis C and interferon-α.

Authors:  F Menconi; A Hasham; Y Tomer
Journal:  J Endocrinol Invest       Date:  2010-02-28       Impact factor: 4.256

Review 6.  Interferon alpha treatment and thyroid dysfunction.

Authors:  Yaron Tomer; Jason T Blackard; Nagako Akeno
Journal:  Endocrinol Metab Clin North Am       Date:  2007-12       Impact factor: 4.741

Review 7.  Interferon induced thyroiditis.

Authors:  Yaron Tomer; Francesca Menconi
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

8.  Genetic analysis of interferon induced thyroiditis (IIT): evidence for a key role for MHC and apoptosis related genes and pathways.

Authors:  Alia Hasham; Weijia Zhang; Vaneet Lotay; Shannon Haggerty; Mihaela Stefan; Erlinda Concepcion; Douglas T Dieterich; Yaron Tomer
Journal:  J Autoimmun       Date:  2013-05-15       Impact factor: 7.094

Review 9.  Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment.

Authors:  Francesca Pastore; Antonio Martocchia; Manuela Stefanelli; Pietro Prunas; Stefania Giordano; Lavinia Toussan; Antonio Devito; Paolo Falaschi
Journal:  World J Hepatol       Date:  2016-01-18

10.  Patterns of interferon-alpha-induced thyroid dysfunction vary with ethnicity, sex, smoking status, and pretreatment thyrotropin in an international cohort of patients treated for hepatitis C.

Authors:  Jennifer S Mammen; Sharon R Ghazarian; Antony Rosen; Paul W Ladenson
Journal:  Thyroid       Date:  2013-08-03       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.